Salmonson Re-elected To Chair EMA's CHMP
This article was originally published in SRA
Executive Summary
Dr Tomas Salmonson has been re-elected to chair the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for a second three-year term1.
You may also be interested in...
New CHMP Chair Sought As Salmonson’s Tenure At Key EMA Panel Ends
Tomas Salmonson, the longstanding chair of the European Medicines Agency's key scientific committee, the CHMP, is being replaced. The Swedish regulator has held the post for six years, the maximum time allowed.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.